Quick answer: BioLean3 Reta vs BioLean2 Tirz comes down to the number of receptor pathways each compound is associated with. BioLean3 Reta GGG is classed as a triple agonist (GLP-1, GIP and glucagon). BioLean2 Tirz GIP belongs to the dual-agonist class (GLP-1 and GIP). Both are sold for laboratory research use only.
What is the main difference between BioLean3 Reta and BioLean2 Tirz?
An agonist is a molecule that binds a receptor and switches it on. A triple agonist is studied for its activity at three receptors at once, a dual agonist at two.
Our product page for BioLean3 Reta names three pathways: GLP-1 signaling, GIP receptor activity and glucagon-related pathways. The extra one compared with BioLean2 Tirz is the glucagon pathway. That is the whole point of the comparison. Researchers who want to look at GLP-1 and GIP signaling alone work with a two-pathway compound. Those who want to add glucagon-related signaling look at a three-pathway one.
BioLean3 Reta vs BioLean2 Tirz side by side
| Feature | BioLean3 Reta GGG | BioLean2 Tirz GIP |
|---|---|---|
| Class | Triple-agonist research compound | Dual-agonist research compound |
| Pathways | GLP-1, GIP, glucagon | GLP-1, GIP |
| Vial sizes in catalog | 10mg and 30mg | 10mg and 30mg |
| Research areas named | Multi-receptor metabolic pathways, appetite and regulatory signaling, energy balance, glucose-associated processes | Overlapping areas, with two receptor pathways instead of three |
| Strength of evidence | Thinner. Three-way receptor interactions are harder to separate in a model. | Somewhat broader. Fewer pathways make results easier to attribute. |
We do not list molecular weight or formula for BioLean3 Reta on its product page, so we have left them out here. The COA is where the measured mass belongs.
What has research examined for each?
The two shared pathways
GLP-1 and GIP are both gut-related signaling pathways. Published laboratory work, mostly in cell assays and animal models, has examined them in connection with glucose-associated processes and appetite signaling. Both compounds sit in this research space.
What the glucagon pathway adds
Glucagon signaling is studied in animal models alongside energy expenditure and liver glucose handling. Researchers propose that pairing it with the other two pathways lets them examine how the signals interact. This is an area of active investigation, and cell and animal results do not translate directly to other settings. We do not summarize outcomes here, because the findings depend heavily on the model.
What is in each vial?
BioLean3 Reta is supplied in a precision-filled 30mg laboratory vial, with a 10mg size also in the catalog. The page describes stability-preserving packaging and batch-controlled manufacturing. Our peptides are synthesized at a WHO/GMP and ISO 9001 certified laboratory in California. You can see the product at BioLean3 Reta GGG 30mg, and the dual-agonist comparison at BioLean2 Tirz GIP 30mg. The fill amount is the same on both, so vial size does not tell you which compound you have.
How do you tell them apart on a COA?
Check three lines. For a full walkthrough, see our line-by-line COA guide.
- Product name and batch number. The name must match the vial, including the 10mg or 30mg size.
- Identity by mass spectrometry. This is the line that separates two compounds. Each has its own molecular mass, and the measured value should match the expected mass for the compound named. A COA that gives no mass cannot confirm which compound is in the vial.
- Purity by HPLC and content per vial. HPLC shows how much of the sample is the main compound, and the peak should be clean. Two different compounds can both show high purity, so purity alone does not prove identity. The content figure should be consistent with the labeled fill.
For a multi-pathway compound, also watch for closely related impurities. Longer, more complex peptides leave more room for truncated or modified sequences during synthesis, which is why synthesis quality matters.
Which one fits which research question?
If the question is about GLP-1 and GIP signaling together, the two-pathway compound is the simpler model. If the question involves glucagon-related pathways as well, BioLean3 Reta is the one associated with all three. Neither choice is a claim about outcomes. The right compound depends on the receptors your model is built around.
Frequently asked questions
Is BioLean3 Reta the same as BioLean2 Tirz GIP?
No. They are separate catalog compounds with different receptor profiles: three pathways for BioLean3 Reta and two for BioLean2 Tirz GIP.
What does GGG mean in BioLean3 Reta GGG?
The three G's line up with the three pathways on the product page: GLP-1, GIP and glucagon.
What is a triple agonist?
It is a molecule studied for its ability to activate three different receptors. In this case they are the GLP-1, GIP and glucagon receptors.
Can HPLC alone tell two compounds apart?
Not reliably. HPLC measures purity, while mass spectrometry confirms identity, so you need both on the COA.
Does the 30mg vial contain a different compound from the 10mg vial?
No. It is the same compound at a different fill amount, and the COA should list the size for the batch.
Are these products for human use?
No. Both are sold strictly for laboratory research and analytical purposes and are not for human or animal use.
Every lot we sell has a Certificate of Analysis you can read before you order. Questions before you buy? Our team is in Chandler, Arizona: (888) 745-1505 or our contact page.
View BioLean3 Reta GGG | 30mgAll products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.